Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.